Aggressive fibromatosis

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 2, 2005, Pages 211-215

  Mendenhall, William M ^a,b   Zlotecki, Robert A ^a   Morris, Christopher G ^a   Hochwald, Steven N ^a   Scarborough, Mark T ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Aggressive fibromatosis; Pharmacologic therapy; Radiotherapy; Surgery

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; APC PROTEIN; BETA CATENIN; CARBOPLATIN; CISPLATIN; CYCLIN D1; CYCLINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GOSERELIN; INTERFERON; KI 67 ANTIGEN; MEGESTROL ACETATE; METHOTREXATE; MITOMYCIN; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PROGESTERONE; TAMOXIFEN; TESTOLACTONE; TOREMIFENE; VINBLASTINE; VINCRISTINE; WNT PROTEIN;

AGE; CANCER RADIOTHERAPY; CANCER SURGERY; DESMOID TUMOR; FIBROMATOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENCE RISK; REVIEW; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; TUMOR LOCALIZATION;

FIBROMATOSIS, AGGRESSIVE; HUMANS;

EID: 17044382904     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000144817.78549.53     Document Type: Review

References (31)

1. Dalén BPM, Bergh PM, Gunterberg BU. Desmoid tumors: a clinical review of 30 patients with more than 20 years' follow-up. Acta Orthop Scand. 2003;74:455-459.
2. Ballo MT, Zagars GK, Pollack A, et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999;17:158-167.
3. Zlotecki RA, Scarborough MT, Morris CG, et al. External beam radiotherapy for primary and adjuvant management of aggressive fibromatosis. Int J Radiat Oncol Biol Phys. 2002;54:177-181.
4. Spear MA, Jennings LC, Mankin HJ, et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys. 1998;40:637-645.
5. De Wever I, dal Cin P, Fletcher CDM, et al. Cytogenetic, clinical, and morphologic correlations in 78 cases of fibromatosis: a report from the CHAMP study group. Mod Pathol. 2000;13:1080-1085.
6. Bridge JA, Swarts SJ, Buresh C, et al. Trisomies 8 and 20 characterize a subgroup of benign fibrous lesions arising in both soft tissue and bone. Am J Pathol. 1999;154:729-733.
7. Pignatti G, Barbanti-Brodano G, Ferrari D, et al. Extraabdominal desmoid tumor. A study of 83 cases. Clin Orthop. 2000;375:207-213.
8. Gronchi A, Casali PG, Mariani L, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol. 2003;21:1390-1397.
9. Tonelli F, Ficari F, Valanzano R, et al. Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifene. Tumori. 2003;89:391-396.
10. Couture J, Mitri A, Lagace R, et al. A germline mutation at the extreme 3′ end of the APC gene results in a severe desmoid phenotype and is associated with overexpression of beta-catenin in the desmoid tumor. Clin Genet. 2000;57:205-212.
11. Bertario L, Russo A, Sala P, et al. Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer. 2001;95:102-107.
12. Tejpar S, Nollet F, Li C, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene. 1999;18:6615-6620.
13. Tejpar S, Li C, Yu C, et al. Tcf-3 expression and β-catenin mediated transcriptional activation in aggressive fibromatosis (desmoid tumour). Br J Cancer. 2001;85:98-101.
14. Saito T, Oda Y, Tanaka K, et al. β-catenin nuclear expression correlates with cyclin D1 overexpression in sporadic desmoid tumours. J Pathol. 2001;195:222-228.
15. American Joint Committee on Cancer. AJCC Cancer Staging Manual, 6th ed, vol 22. New York: Springer; 2002:193-200.
16. Hoos A, Lewis JJ, Urist MJ, et al. Desmoid tumors of the head and neck-a clinical study of a rare entity. Head Neck. 2000;22:814-821.
17. Carton CN, O'Sullivan B, Bell R, et al. Aggressive fibromatosis: optimisation of local management with a retrospective failure analysis. Radiother Oncol. 1995;34:17-22.
18. Keus R, Bartelink H. The role of radiotherapy in the treatment of desmoid tumours. Radiother Oncol. 1986;7:1-5.
19. Acker JC, Bossen EH, Halperin EC. The management of desmoid tumors. Int J Radiat Oncol Biol Phys. 1993;26:851-858.
20. Janinis J, Patriki M, Vini L, et al. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol. 2003;14:181-190.
21. Leibel SA, Wara WM, Hill DR, et al. Desmoid tumors: local control and patterns of relapse following radiation therapy. Int J Radiat Oncol Biol Phys. 1983;9:1167-1171.
22. Merchant NB, Lewis JJ, Woodruff JM, et al. Extremity and trunk desmoid tumors. A multifactorial analysis of outcome. Cancer. 1999; 86:2045-2052.
23. Brueckl WM, Preuss JMM, Wein A, et al. Ki-67 expression and residual tumour (R) classification are associated with disease-free survival in desmoid tumour patients. Anticancer Res. 2001;21:3615-3620.
24. Nuyttens JJ, Rust PF, Thomas CR Jr, et al. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: a comparative review of 22 articles. Cancer. 2000;88:1517-1523.
25. Azzarelli A, Gronchi A, Bertulli R, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer. 2001;92:1259-1264.
26. Mace J, Biermann JS, Sondak V, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer. 2002;95: 2373-2379.
27. Okuno SH, Edmonson JH. Combination chemotherapy for desmoid tumors. Cancer. 2003;97:1134-1135.
28. Lindor NM, Dozois R, Nelson H, et al. Desmoid tumors in familial adenomatous polyposis: A pilot project evaluating efficacy of treatment with pirfenidone. Am J Gastroenterol. 2003;98:1868-1874.
29. De Pas T, Bodei L, Pelosi G, et al. Peptide receptor radiotherapy: a new option for the management on aggressive fibromatosis on behalf of the Italian Sarcoma Group. Br J Cancer. 2003;88:645-647.
30. Park HC, Pyo HR, Shin KH, et al. Radiation treatment for aggressive fibromatosis: findings from observed patterns of local failure. Oncology. 2003;64:346-352.
31. Schulz-Ertner D, Zierhut D, Mende U, et al. The role of radiation therapy in the management of desmoid tumors. Strahlenther Onkol. 2002;178:78-83.